Merck to Ask FDA for Emergency Approval of Its New Antiviral Pill for COVID
FRIDAY, Oct. 1, 2021 (HealthDay News) — Pharmaceutical giant Merck & Co. said Friday that it will seek federal approval for emergency use of its new antiviral pill molnupiravir, after a clinical trial showed the drug halved the risk of hospitalizatio…
Learn MoreHealth Highlights: Oct. 1, 2021
Merck to seek emergency approval for its new COVID antiviral pill: In a trial of the drug molnupiravir, the risk of hospitalization and death was halved when given to high-risk patients within five days of infection. Read moreHas the pandemic made the…
Learn MoreHealth Highlights: Sept. 30, 2021
CDC issues urgent plea for pregnant women to get vaccinated: With only a third of women in this group immunized, health officials made a strong push for getting the shots. Read moreNew report finds toxins in baby foods a continuing problem: Despite an…
Learn MoreHealth Highlights, Sept. 29, 2021
Side effects of Pfizer booster shots are no different than with first two doses: The reassuring report comes as millions of Americans sign up for their third dose of the vaccine. Read moreNew tests for colon, prostate cancer show promise: In a pair of…
Learn MoreHealth Highlights, Sept. 28, 2021
Delta variant convinced many to get vaccinated, poll finds: But the Kaiser Family Foundation’s latest survey also revealed that among unvaccinated Americans, nearly 75% say they believe the need for booster shots proves the vaccines don’t work. Read m…
Learn MoreHealth Highlights: Sept. 27, 2021
Had COVID before and think you’re immune? Think again: Not all infections are created equal, with antibody responses varying wildly, experts say. Read moreRetirees who cruise the internet stay sharp: Those who logged on more often posted substantially…
Learn More9/24 Health Highlights, Sept. 24, 2021
Could a computer program help doctors spot breast cancer? New research says it can, and using it might reduce the need for extra testing. Read moreSaline spray slowed COVID’s spread in lab study: It cut replication of the virus by 88% in tests of infe…
Learn MoreHealth Highlights: Sept. 23, 2021
Here are some of HealthDay’s top stories for Thursday, Sept. 23:FDA approves Pfizer booster shot for seniors, high-risk folks: Under the emergency use authorization, the booster shots should be given at least six months after a person is fully vaccina…
Learn MoreHealth Highlights: Sept. 20, 2021
Here are some of HealthDay’s top stories for Monday, Sept. 20:Lower dose of Pfizer vaccine works in kids as young as 5: The pharmaceutical giant announced Monday that a dose that is one-third the strength of adult doses triggered a robust immune respo…
Learn MoreLower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company Says
MONDAY, Sept. 20, 2021 (HealthDay News) — A smaller dose of Pfizer’s coronavirus vaccine safely triggers a strong immune response in children as young as 5, the company announced Monday morning. “Over the past nine months, hundreds of millions of peo…
Learn More